TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

NASDAQ:TSHA • US8776191061

4.53 USD
-0.04 (-0.88%)
At close: Feb 27, 2026
4.53 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

TSHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. The financial health of TSHA is average, but there are quite some concerns on its profitability. TSHA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TSHA had negative earnings in the past year.
  • TSHA had a negative operating cash flow in the past year.
  • TSHA had negative earnings in each of the past 5 years.
  • In the past 5 years TSHA always reported negative operating cash flow.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • TSHA has a Return On Assets of -31.57%. This is in the better half of the industry: TSHA outperforms 65.45% of its industry peers.
  • TSHA has a better Return On Equity (-45.63%) than 67.75% of its industry peers.
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TSHA has been increased compared to 1 year ago.
  • Compared to 5 years ago, TSHA has more shares outstanding
  • The debt/assets ratio for TSHA is higher compared to a year ago.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • TSHA has an Altman-Z score of 4.66. This indicates that TSHA is financially healthy and has little risk of bankruptcy at the moment.
  • TSHA has a better Altman-Z score (4.66) than 71.59% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that TSHA is not too dependend on debt financing.
  • TSHA has a Debt to Equity ratio of 0.23. This is in the lower half of the industry: TSHA underperforms 65.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 4.66
ROIC/WACCN/A
WACC8.65%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 10.48 indicates that TSHA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 10.48, TSHA belongs to the top of the industry, outperforming 83.11% of the companies in the same industry.
  • TSHA has a Quick Ratio of 10.48. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
  • TSHA has a Quick ratio of 10.48. This is amongst the best in the industry. TSHA outperforms 83.11% of its industry peers.
Industry RankSector Rank
Current Ratio 10.48
Quick Ratio 10.48
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for TSHA have decreased strongly by -152.38% in the last year.
  • Looking at the last year, TSHA shows a very negative growth in Revenue. The Revenue has decreased by -36.36% in the last year.
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • TSHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.07% yearly.
  • TSHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.78% yearly.
EPS Next Y-2.46%
EPS Next 2Y-10.41%
EPS Next 3Y-13.5%
EPS Next 5Y28.07%
Revenue Next Year-21.25%
Revenue Next 2Y-27.82%
Revenue Next 3Y58.49%
Revenue Next 5Y126.78%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • TSHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as TSHA's earnings are expected to decrease with -13.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.41%
EPS Next 3Y-13.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TSHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (2/27/2026, 8:00:02 PM)

After market: 4.53 0 (0%)

4.53

-0.04 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-04
Inst Owners97.33%
Inst Owner Change1.21%
Ins Owners1.03%
Ins Owner Change4.9%
Market Cap1.24B
Revenue(TTM)6.31M
Net Income(TTM)-99.93M
Analysts85
Price Target11.22 (147.68%)
Short Float %22.99%
Short Ratio18.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.52%
Min EPS beat(2)-9.04%
Max EPS beat(2)-0.01%
EPS beat(4)2
Avg EPS beat(4)5.88%
Min EPS beat(4)-9.04%
Max EPS beat(4)17.32%
EPS beat(8)5
Avg EPS beat(8)124.3%
EPS beat(12)7
Avg EPS beat(12)85.18%
EPS beat(16)9
Avg EPS beat(16)64.99%
Revenue beat(2)1
Avg Revenue beat(2)-39.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)21.32%
Revenue beat(4)2
Avg Revenue beat(4)-10.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)52.45%
Revenue beat(8)5
Avg Revenue beat(8)-3.64%
Revenue beat(12)8
Avg Revenue beat(12)34.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.99%
PT rev (3m)12.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 196.65
P/FCF N/A
P/OCF N/A
P/B 5.67
P/tB 5.67
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.02
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.26%
Cap/Sales 7.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.48
Quick Ratio 10.48
Altman-Z 4.66
F-Score3
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-2.46%
EPS Next 2Y-10.41%
EPS Next 3Y-13.5%
EPS Next 5Y28.07%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-21.25%
Revenue Next 2Y-27.82%
Revenue Next 3Y58.49%
Revenue Next 5Y126.78%
EBIT growth 1Y-23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.18%
EBIT Next 3Y-22.23%
EBIT Next 5YN/A
FCF growth 1Y-76.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.7%
OCF growth 3YN/A
OCF growth 5YN/A

TAYSHA GENE THERAPIES INC / TSHA FAQ

What is the ChartMill fundamental rating of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSHA.


Can you provide the valuation status for TAYSHA GENE THERAPIES INC?

ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.


What is the profitability of TSHA stock?

TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TAYSHA GENE THERAPIES INC?

The Earnings per Share (EPS) of TAYSHA GENE THERAPIES INC (TSHA) is expected to decline by -2.46% in the next year.